Chronic inflammation’s influence on TP53 mutations in leukemia evolution explored in new study

Researchers performed a multi-omics evaluation of HSPCs obtained from individuals with myeloproliferative neoplasms transforming to TP53-related secondary forms of acute myeloid leukemia.

Q1 2024 Digital Health Funding: A Reset & Refocus on Outcomes

What You Should Know: – Q1 2024 Digital health funding in the U.S. reached $2.7B across 133 deals, with an average deal size of $20.6M,

April 10, 2024

Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease – Biotech Investments

EQS-News: ABIVAX / Key word(s): Study Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease 02.02.2024 /

February 6, 2024

Illustrating the safety of a new drug treatment designed for spinal cord injury

New orally available drug for spinal cord injury found to be safe and tolerable in healthy participants.

August 11, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.